PHMB-loaded PDMS and its antimicrobial properties for biomedical applications.

Given the global panorama of demands in the health area, the development of biomaterials becomes irreducible for the maintenance and/or improvement in the quality of life of the human being. Aiming to reduce the impacts related to infections in the healing processes of the dermal structure, the present work proposes the development of polydimethylsiloxane (PDMS) based membranes with the incorporated polyhexamethylenebiguanide (PHMB) antimicrobial agent. In the present study, the antimicrobial and antibiofilm properties of polydimethylsiloxane (PDMS) films incorporated with 0.1, 0.3, and 0.5% (w/w) of polyhexamethylene biguanide (PHMB) were evaluated, aiming the development of a protective biomaterial that avoids cutaneous infections from the autochthonous and allochthonous microbiota. The disk diffusion of PHMB-loaded PDMS has shown the growth inhibition of Escherichia coli (ATCC 9637), Pseudomonas aeruginosa (ATCC 27953), Acinetobacter baumannii (ATCC 19606), Staphylococcus aureus (ATCC 6538), Staphylococcus epidermidis (ATCC 12228), Streptococcus pyogenes (ATCC 19615), Bacillus subtilis (ATCC 6633) and also yeast-like fungi Candida albicans, all microorganisms found on the epidermal surface. Likewise, the present study demonstrated low cytotoxicity of the PHMB-loaded PDMS on HaCaT and L929 cells at lower concentrations (0.1% w/w), indicating the possibility of using the developed material as a dressing for wounds, burns, and post-surgical procedures.

Antitumor activity of Brazilian red propolis fractions against Hep-2 cancer cell line.

Continuous increases in the rates of tumor diseases have highlighted the need for identification of novel and inexpensive antitumor agents from natural sources. In this study, we investigated the effects of enriched fraction from hydroalcoholic Brazilian red propolis extract against Hep-2 cancer cell line. Initially 201 fractions were arranged in 12 groups according to their chromatographic characteristics (A-L). After an in vitro cell viability screening, J and L were further selected as promising enriched fractions for this study. The chemical characterization was performed and Biochanin A, Formononetin, and Liquiritigenin compounds were quantified. Through MTT viability assay and morphological changes observed by Giemsa and DAPI staining, the results showed that red propolis inhibited cancer cells growth. Flow cytometry results indicated effects that were partly mediated through programmed cell death as confirmed by externalization of phosphatidylserine, DNA cleaved assay, increase at SUB G1-G0 phase in cell cycle analysis and loss of mitochondrial membrane potential. In conclusion, our results demonstrated that red propolis enriched fractions promoted apoptotic effects in human cancer cells through the mechanisms involving mitochondrial perturbation. Therefore, red propolis fractions contain candidate agents for adjuvant cancer treatment, which further studies should elucidate the comprehensive mechanistic pathways.

Proteomic analysis identifies differentially expressed proteins after red propolis treatment in Hep-2 cells.

Here we investigated alterations in the protein profile of Hep-2 treated with red propolis using two-dimensional electrophoresis associated to mass spectrometry and apoptotic rates of cells treated with and without red propolis extracts through TUNEL and Annexin-V assays. A total of 325 spots were manually excised from the two-dimensional gel electrophoresis and 177 proteins were identified using LC-MS-MS. Among all proteins identified that presented differential expression, most were down-regulated in presence of red propolis extract at a concentration of 120 µg/mL (IC50): GRP78, PRDX2, LDHB, VIM and TUBA1A. Only two up-regulated proteins were identified in this study in the non-cytotoxic (6 µg/mL) red propolis treated group: RPLP0 and RAD23B. TUNEL staining assay showed a markedly increase in the mid- to late-stage apoptosis of Hep-2 cells induced by red propolis at concentrations of 60 and 120 µg/mL when compared with non-treated cells. The increase of late apoptosis was confirmed by in situ Annexin-V analysis in which red propolis extract induced late apoptosis in a dose-dependent manner. The differences in tumor cell protein profiles warrant further investigations including isolation of major bioactive compounds of red propolis in different cell lines using proteomics and molecular tests to validate the protein expression here observed.

Chemical characterization, antioxidant and cytotoxic activities of Brazilian red propolis.

Propolis is known for a long time for its health benefits and biological activities. Here, the red variety from the northeast of Brazil was chemically analyzed and extracts were investigated regarding their antioxidant and antitumor activity. Hydroalcoholic extracts, obtained from the red propolis, revealed polyphenol content, 2,2-diphenyl-1-picrylhydrazyl scavenging potential and enzymatic activities for catalase-like and superoxide dismutase-like. Cytotoxic activity was evaluated for human laryngeal epidermoid carcinoma cell (Hep-2), human cervical adenocarcinoma (HeLa) and human normal epithelial embryonic kidney (Hek-293). Survival analysis for non-tumor cell line showed greater IC50 compared to tumor cell lines, suggesting an increased sensitivity that may correlate with the higher proliferative index of the tumor vs. normal cells. Our results indicate that the Brazilian red propolis is capable of inhibiting cancer cell growth and constitutes an excellent source of antioxidant and antitumor natural agent.